EDAP TMS S.A. (FOCL)
FOCL trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1041934/000110465926034528/0001104659-26-034528-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | FOCL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | France |
| IPO year | Not reported by the screener |
| SEC CIK | 0001041934 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $70.5M |
| Net income | -$29.2M |
| Operating income | -$24.7M |
| Net margin | -41.5% |
| Operating margin | -35.0% |
| Revenue growth | +1.6% |
| Cash | $20.5M |
| Total assets | $79.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $56.3M cash; operating cash flow -$3.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG SA, Lyon, France | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $451K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.8M | -$4.5M | -$4.0M | $56.3M | $36.0M | $87.5M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $13.2M | -$14.5M | -$3.7M | $21.5M | $39.9M | $85.5M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $17.8M | -$9.1M | -$3.0M | $15.0M | $24.3M | $81.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $46.7M | -$9.5M | -$2.5M | $20.5M | $22.4M | $78.3M | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $7.8M | -$5.9M | -$3.9M | $12.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $9.5M | -$6.4M | -$4.7M | $19.1M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $14.3M | -$7.4M | -$5.3M | $24.7M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-05-14 |
Source: SEC EDGAR submissions feed, 497 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.1% |
| 1 month | -22.6% |
| 3 months | -29.8% |
| Year to date | -1.2% |
| 1 year | +53.3% |
| From 52-week high | -48.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier